Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

Allogeneic CAR-T therapy AVC-201 in AML positive for CD123

Blood (2025) 146 (Supplement 1): 3426.

https://doi.org/10.1182/blood-2025-3426

Published: 2025

Journal Articles

Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024

Christian Rausch, Adrian Gottschlich, Giulia Magno, Stefanie Griesshammer, Tobias Tix, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Veit Buecklein

Blood (2025) 146 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2025-4418

Published: 2025

Journal Articles

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03

Blood (2025) 146 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2025-3373

Published: 2025

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Giulia Rappa, Frank Ziemann, Kieron White, Amelie Muth, Cristina Zucchinetti, Maja Rothenberg-Thurley, Tobias Tix, Agnese Petrera, Bianka Ksienzyk, Charlotte Bentenrieder, Fabian Müller, Veit Buecklein, Kai Rejeski, Marion Subklewe

Blood (2025) 146 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2025-2366

Published: 2025

Journal Articles

Pre-treatment vaccine seroprotection is markedly lower in BCMA-CAR vs CD19-CAR recipients with limited post-therapy modulation

Giulia Magno, Elif Apak, Savanna Süß, Giulia Rappa, Patricia M. Späth, Sophia Stock, Alessandra Holzem, Wajma Shahbaz, Tobias Tix, Bernhard Ismann, Judith S. Hecker, Florian Bassermann, Sebastian Theurich, Michael Von Bergwelt, Kai Rejeski, Oliver T. Keppler, Marion Subklewe, Veit Buecklein

Blood (2025) 146 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2025-6355

Published: 2025

Journal Articles

Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy

Alessandra Holzem, Michael Ingrisch, Anna Magee, Veronika Kezzo, Tobias Tix, Sophia Stock, Giulia Magno, Wajma Shahbaz, Michaela Braxenthaler, Michael Von Bergwelt, Wolfgang Kunz, Veit Buecklein, Sebastian Theurich, Marion Subklewe, Kai Rejeski

Blood (2025) 146 (Supplement 1): 6331.

https://doi.org/10.1182/blood-2025-6331

Published: 2025

Journal Articles

Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights

Veit Buecklein, Katharina Mueller, Florian Schoeberl, Adrian Gottschlich, Giulia Rappa, Gerulf Haenel, Tobias Tix, Steffen Tiedt, Sophia Stoecklein, Johannes Gnoerich, Nathalie Albert, Matthias Brendel, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Louisa von Baumgarten

Blood (2025) 146 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2025-4172

Published: 2025

Journal Articles

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Blood (2025) 146 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2025-5124

Published: 2025

Journal Articles

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

David Cordas Dos Santos, Hannah Thurisch, Jingke Tu, Daniel Heilpern-Mallory, Amar Hadzic, Martin Kirmaier, Werner Schmitz, Martin Vaeth, Sabine Oganesian, Adriano Carboniero, Ludovica Vona, Viktoria Blumenberg, Veit Buecklein, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Sebastian Theurich

Blood (2025) 146 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2025-5887

Published: 2025

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL

Viktoria Blumenberg, Galina Busch, Stephan Baumann, Sabine Schmidt, Hanna Schuhmacher, Michael Winkelmann, Friederike Hildebrandt, Kai Rejeski, Franziska J Vettermann, MD, Wolfgang G. Kunz, Michael von Bergwelt, Veit Buecklein, Christoph Stein-Thöringer, Marion Subklewe

Blood (2021) 138 (Supplement 1): 2792.

https://doi.org/10.1182/blood-2021-153117

Published: 2021

Journal Articles

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Viktoria Blumenberg, MD, Maria-Luisa Schubert, MD, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, MD, Eran Elinav, Christian Schmidt, MD, Veit Buecklein, MD, Carsten Müller-Tidow, MD, Peter Dreger, MD, Michael von Bergwelt, MD PhD, Michael Schmitt, MD, Marion Subklewe, MD, Christoph Stein-Thöringer, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141210

Published: 2020

Journal Articles

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Maximilian Alexander A Rohnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Rollig, MD MSC, Martin Bornhäuser, MD, Veit Buecklein, MD, Marion Subklewe, MD, Stefan W Krause, Simon Voelkl, Tobias Berg, Michael A Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard F. Schlenk, Sylvie D Freeman, Uta Oelschlägel

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-138683

Published: 2020

Journal Articles

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Veit Buecklein, MD, Viktoria Blumenberg, MD, Josephine Ackermann, Christian Schmidt, MD, Kai Rejeski, MD, Niklas Mueller, MD, Anna Reischer, MD, Louisa von Baumgarten, MD, Florian Schoeberl, MD, Andreas Humpe, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142932

Published: 2020

Journal Articles

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Alessia Fraccaroli, MD, Sarah Haebe, MD, Heidrun Drolle, Elena Stauffer, Elena.Stauffer@MDuni-muenchen.de, Veit Buecklein, MD, Dusan Prevalsek, Michael von Bergwelt, MD PhD, Johanna Tischer

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142708

Published: 2020

Journal Articles

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Kai Rejeski, MD, Carolina Berger, Liv Jentzsch, Semjon Willier, MD, Viktoria Blumenberg, MD, Veit Buecklein, MD, Christoph Faul, MD, Christian Schmidt, MD, Michael von Bergwelt, MD PhD, Tobias Feuchtinger, MD, Wolfgang Bethge, MD, Francis A. Ayuk, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141833

Published: 2020

Journal Articles

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, MD, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, MD, Karsten Spiekermann, MD, Oliver Weigert, MD, Sebastian Theurich, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137421

Published: 2020

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Allogeneic CAR-T therapy AVC-201 in AML positive for CD123

Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Pre-treatment vaccine seroprotection is markedly lower in BCMA-CAR vs CD19-CAR recipients with limited post-therapy modulation

Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy

Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only